



Primary cancer of the breast is the most prevalent site‑specific 
cancer seen in women in Nigeria and globally, beside 
nonmelanoma skin malignancy.[1-8] Data from most Nigerian 
cancer registries suggest increasing occurrence of breast 
cancer (BC), with more than a threefold increase in its incidence 
in a decade (1992–2001) reported in Ibadan.[1-7,9] BC-related 
mortality is second only to that of lung cancer globally.
The now-known disparate nature of BC in its histology, molecular 
biology, clinical behavior, and outcomes informs the need for 
personalized treatment of both the local and systemic disease 
by global best practice guidelines.[10-13] This individualized 
management approach espouses local and systemic management 
of BC by appropriate combination of surgery and/or irradiation, 
as well as chemotherapy regimens with or without hormonal 
therapy or targeted monoclonal antibody.[10-13] Molecular typing 
of BC is crucial to achieving this tailored treatment.[11-13] Breast 
carcinomas are categorized into four molecular phenotypes: 
triple negative breast cancer (TNBC), luminal A, luminal B, and 
HER-2/Neu-enriched. This is based on the pattern of expression 
of progesterone receptor (PR), oestrogen receptor (ER), and 
Human epidermal growth factor receptor 2/Neu (HER-2/Neu) 
determined using either molecular techniques such as in situ 
hybridization (ISH), fluorescence ISH (FISH), and polymerase 
chain reaction, or surrogate immunohistochemical methods.[11-14]
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These molecular phenotypes have peculiar clinicopathologic 
features, differing sensitivity to chemotherapeutic, hormonal, 
and targeted monoclonal antibody agents, and overall survival 
outcomes.[10-16]
Hence, molecular subtyping is pivotal for selection of systemic 
drug combinations, prediction of response, prognostication, 
genetic counselling, and planning of screening programs.[10-14] 
Molecular phenotyping using immunohistochemical procedure 
which is the relatively cheaper and easier to set-up method 
for routine clinical use is the preferred surrogate approach 
to molecular subclassification of breast carcinoma. We 
described the molecular phenotypes of breast carcinomas in 
the Pathology Unit, Asokoro District Hospital, Abuja, Nigeria, 
based on their ER, PR, and HER-2/Neu receptor status and 
compared our results with studies from Nigeria and Africa.
MaterIals and Methods
This was a retrospective review of 136 histopathologically 
diagnosed breast carcinomas for which biodata and 
pathology and molecular (ER, PR, and HER2) data were 
available in the Pathology Unit of Asokoro District Hospital, 
Abuja, Nigeria, from January 1, 2012, to December 31, 
2019. For each case of cancer of the breast, we extracted 
clinicopathological data - patients’ age and sex, tumor 
laterality, histological subtypes, histological grades and the 
immunohistochemical results of ER, PR, and HER-2/Neu 
status of the breast carcinoma from patients’ request forms 
and histopathology reports archived in the Unit during the 
period under review. The histology slides of each case of BC 
had been reviewed to confirm the diagnoses and grading. 
The cancers were classified in accordance with the 2012 
WHO International Classification of breast Tumours[15] and 
graded according to the Nottingham grading system.[16] Breast 
carcinomas with missing immunohistochemical profiles of 
ER, PR, and HER2 in the archive were excluded from the 
study. The avidin-biotin complex method with ABCAM 
(Cambridge, MA, USA) monoclonal antibodies was used for 
the immunostainig procedure.
Receptors status were scored, and molecular subtypes 
allocated utilizing the Joint American Society of Clinical 
Oncology/College of American Pathologists and the St. 
Gallen International Expert Consensus (2013) guidelines and 
recommendations bar utilizing FISH to ascertain the HER2 
status when it is equivocal on immunohistochemistry (2+).[11-13] 
According to the guideline, brown nuclear immunostain 
of ≥10% of neoplastic cells at light microscopy was adjudged 
as positive for ER (ER+) and PR (PR+) expression, while 
score 3+ brown membrane immunostaining of >10% of 
neoplastic cells was adjudged as immunopositive for HER2 
expression (HER2+). Lack of brown nuclear immunostaining 
of BC cells was considered negative for ER (ER−) and 
PR (PR−) while staining of scores 0, 1+, and 2+ was 
deemed negative for Her2 (Her2−) since facility for FISH 
(equivocal 2+) is absent in our centre (two cases of 2 + where 
seen in our study). Based on the immunostaining profile, the 
molecular phenotypes were classified as luminal A cancers 
(PR+/ER+, HER2 − or PR−/ER+, HER2 − or PR+/ER−, HER2−), 
luminal B cancers (PR+/ER+, HER2 + or PR−/ER+, HER2 + or 
PR+/ER−, HER2+), triple-negative BCs (PR−/ER−, HER2,−) 
and HER2-enriched cancers (PR−/ER−, HER2+). The 
resultant data were managed using Microsoft Excel software 
program (Microsoft Corporation 2016, New York, USA) and 
displayed using tables and chart.
results
Eight hundred and thirty-eight surgical breast lesions were 
diagnosed during the period of the study. Primary BCs 
constituted 30.3% (254/838) of all the breast lesions, with 
carcinomas making up 98.4% (250/254). Immunohistochemical 
data (ER, PR, and HER2) were available for 136 (54.4%) of 
these carcinomas. The age of the patients ranged from 17 to 
74 years and the mean age was 47.3 ± 11.7 at diagnosis with 
about 60% (81/136) of the patients aged ≤50 years. All the 
affected patients were females, except for one male teenager. 
The most prevalent histological subtype of breast carcinoma was 
invasive carcinoma, no special type (NST) (94.12%, 128/136), 
followed in the distant by mucinous carcinoma (2.94%). 
A case (0.74%) each of invasive lobular, invasive cribriform, 
invasive papillary, and medullary carcinomas was seen during 
the period of the study. Grade II (59.5%, 81/136) tumors 
were the most common tumor grade encountered. Grade I 
and Grade III tumors constituted 1.5% (2) and 24.3% (33), 
respectively. The results of the immunohistochemical staining 
showed that ER-, PR-, and HER-2/Neu-positive cases 
were 43.4% (59/136), 39% (53/136), and 27.2% (37/136), 
respectively, of the breast. Conversely, the number of breast 
carcinomas that immunostained negatively for ER, PR, and 
HER2 was 56.6% (77/136), 61% (83/136), and 72.8% (99/136), 
respectively [Table 1].
Triple-negative breast carcinoma (39%, 53/136) was the 
most common molecular phenotype, followed by luminal 
A (33.8%, 46/136) and luminal B (14.7%, 20/136), while 
HER2-enriched (12.5%, 17/136) was the least common 
molecular subtype in our series [Figure 1]. Photomicrographs 
of positive immunostains are shown in Figures 2-4, while those 
of negative immunostains are shown in Figures 5-7.
The mean age of patients with triple-negative BC (TNBC) 
was 46.1 ± 12.6 (range of 17–74 years). TNBC peaked in 
the fourth decade and became relatively rare after the sixth 
decade. Almost 42% (22/53) of the patients with TNBC were 
young women (≤40 years) and women ≤50 years make up 
64% (34/53) of all the TNBC patients [Table 2].
dIscussIon
At diagnosis, the average age of our patients was 47.3 years, 
with almost 60% of the affected patients being ≤ 50 years old, 
and this is congruent with the reported mean age for women 
with breast cancers in Nigeria and Africa.[7,9,17-38] The peak 
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age range of the index study (31–40 years) is the same as the 
ones documented in Jos[19] and Uyo,[29] but it is a decade earlier 
than those recorded in Kano,[17] Lagos,[22] and Nnewi.[27] While 
differences in sample sizes and study designs may explain this 
disparity, our finding authenticates the documented fact that 
BC occurs earlier in the women of African ancestry compared 
to their Caucasian counterparts, attributed to aggressive 
biogenetic factors, changing carcinogenic environmental 
factors, and shorter life expectancy.[39-41,43]
Invasive carcinoma, NST was the most prevalent histologic 
subtype of BC in our study, like all series from Nigeria 
and Africa.[17-36] However, while our reported relative 
frequency (94.12%) of invasive carcinoma, NST is in consonant 
with those recorded in Lagos,[22,23] Nnewi,[27] Angola,[32] and 
Eritrea,[33] it is higher than most studies in Nigerian and African 
with a reported range of 73.2%–88%.[17-21,24-26,28-31,33-35] This 
is likely due to the varying small sample sizes of the mainly 
hospital-based studies across the continent.
The predominant grade of tumors in this work is 
Grade II (59.5%) in conformity with most Nigerian[22,23,27,29] 
and African series.[32,33,36,37] It is, however, in contrast to findings 
from other Nigerian[17,18,25,30] and African[34,35] studies which 
reported a preponderance of Grade III BCs. All the previous 
studies though reported an overwhelming majority of higher 
Grade (II and III) tumors, typical of BCs in women of African 
extraction.[40,41] We, thus, agree with Chowdhoury et al.[42] 
that the discrepancy in findings of higher tumor grades in the 
literature reviewed may have been influenced by intra‑ and 
inter-observer variability in BC grading.
Our study revealed that most carcinomas did not express 
hormonal receptors (ER− - 56.6%, PR− - 61%) [Figures 5-7]. 
This parallels the nonexpression of ER− (57.7%) and 
PR− (62.6%), ER− (75.0%) and PR− (62.2%), ER− (61.6%) 
and PR− (70.0%), ER− (85.9%) and PR− (90.1%), and 
ER− (93.0%) and PR− (97.9%) documented in Nnewi,[27] 
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Figure 1: Pie chart showing the frequency distribution of the molecular 
phenotypes of breast carcinoma
Figure 2: Photomicrograph of breast carcinoma immunostained positively 
for estrogen receptor showing strong diffuse nuclear staining of invasive 
breast carcinoma cells (Immunohistochemistry, ×40)
Figure 3: Photomicrograph of breast carcinoma immunostained positively 
for progesterone receptor positive; 5 + 3 strong diffuse nuclear staining 
of invasive breast carcinoma cells (Immunohistochemistry, ×40)
Figure 5: Photomicrograph of breast carcinoma immunostained 
negatively for estrogen receptor showing complete absence of nuclear 
staining of invasive breast carcinoma cells (Immunohistochemistry, ×40)
Figure 4: Photomicrograph of breast carcinoma immunostained positively 
for HER2; 3+ showing diffuse intense membrane staining of invasive 
breast carcinoma cells (Immunohistochemistry, ×40)
Figure 6: Photomicrograph of breast carcinoma immunostained 
negatively for progesterone receptor showing complete absence of nuclear 
staining of invasive breast carcinoma cells (Immunohistochemistry, ×40)
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Jos,[20] Ile-Ife,[25] Benin,[30] and Lagos,[23] respectively, in 
Nigeria as well in Ghana[37] and Angola[32] with non-expression 
rates of ER− (67.9%) and PR− (64.4%) and ER− (86.5%) and 
PR− (90.8%), respectively. In contrast, higher hormonal receptor 
positivity was reported in Ibadan[24] (ER+ - 65.1%, PR+ - 54.7%), 
a private facility in Lagos[21] (ER+ - 54.2%, PR+ - 50%) and 
Morocco[36] (ER+ - 64.2%, PR+ - 66.9%). We are unsure if 
these differences in the hormonal expression pattern within the 
country and continent with a tendency toward non-expression 
of hormonal receptors are truly reflective of the intrinsic 
biologic characteristics of the carcinomas. Eng et al.,[41] in 
their review of receptor‑defined subtypes of BC in Indigenous 
African Populations, reported significant disparity in the 
documented frequencies of hormonal receptor profile of BCs in 
the continent. They posited that the heterogeneity may be due to 
differences in the tumor pathologic characteristics, differences 
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in the prevalence of risk factors for specific subtype, and 
differences in the quality control of preanalytic and analytical 
handling of tumor specimens.
Triple-negative breast carcinomas (TNBCs) were the most 
frequent molecular phenotype of the cases reviewed in our 
study, affecting 42% of young women aged ≤40 years. In a 
similar vein, researchers in virtually all geopolitical regions 
in Nigeria[17-19,22,23,25-27,29] as does Seshie et al.[37] in Ghana 
reported relative predominance of the triple-negative BC 
in their series. The index 39% relative frequency of TNBC 
is similar to the 40.7% recorded by Ukah et al.[27] in Nnewi 
and 41.3% documented by Emmanuel et al.[19] in Jos, but it 
is lower than values cited by previous works with reported 
relative frequency range of 42.1%–87%.[17,18,22,23,25,26,29] Like 
these studies, our value is higher than the documented figures 
from the United States and United Kingdom (15%–25%).[40,43] 
While we cannot adduce a definite explanation for the 
extensive range of proportions reported within the country 
for TNBC, we hypothesize that variable small sample 
sizes (range 20–235), differential level of quality control 
of preanalytical and analytic factors, and variability in 
immunohistochemical processes may play a role. The 
implication, however, of the predominant TNBC is that most 
of our young women were affected by a BC molecular subtype 
with limited response to platinum-based chemotherapy and 
intractable to targeted endocrine and monoclonal antibody 
therapies. This provides the biomolecular basis which in part 
explains the dire outcome noted for Nigerian BC patients.[9,38,43] 
The work by Agboola et al.,[43] which compared Nigerian and 
the UK grade-matched BC patients, showed that Nigerian 
patients have a fourfold likelihood to have TNBC with basal 
phenotype than White UK women with significantly poorer 
survival statistics.
Luminal A and luminal B together represented the largest 
group with luminal A molecular phenotype representing the 
second predominant specific subtype in our study. Luminal 
A phenotype accounted for 33.8% of all the phenotypes, and 
54.3% of the cases seen affected women aged ≤50‑year‑old. 
Luminal A was the most common phenotype reported by 
Adebamowo et al.[24] in Ibadan (77.6%), Omoruyi et al.[28] 
in Calabar (52.4%), Oboma et al.[31] in Bayelsa (54.1%), 
and Nwafor and Keshinro[21] in a private setting (39.6%) 
in Nigeria as well in Eritrea (55.6%),[33] Angola (45%),[32] 
Morocco (42%),[36] Ethiopia (40%),[34] and Guinea (34.5%).[35] 
While ethnic comparative studies have shown that Luminal 
A BCs are predominant in Caucasian women compared to 
African and American Black women, reproductive factors and 
age at diagnosis have also been shown to affect the incidence 
of ER‑positive cancers and could explain the differential 
distribution within Nigeria and the continent.[10,39,43]
Luminal B cancers were seen in 20 (14.7%) patients 
and represented the third most frequent phenotype. This 
rate is similar to findings in Maiduguri (13.2%)[18] and 
Calabar (12.93%)[28] but higher than values reported in 
Figure 7: Photomicrograph of breast carcinoma immunostained 
negatively for HER2; 1+ showing sparse incomplete membrane staining 
of invasive breast carcinoma cells, (Immunohistochemistry, ×40)
Table 1: Baseline Clinicopathological and Molecular 
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Kano (6.7%)[17] and Nnewi (4.9%).[27] ER-positive cancers 
are sensitive to the endocrine agent tamoxifen with variable 
chemosensitivity and have a better overall prognosis relative 
to TNBC and HER2/Neu-enriched cancers.[10,13,39,43]
HER2/Neu-enriched carcinomas were the least common 
molecular type in our series, accounting for 12.5%. This 
finding is in keeping with the high non over‑expression of 
HER-2/Neu pattern across Nigeria[19-21,23-25,27,43] and Africa,[32-38] 
with reported proportion ranges from 68.8% to 96.2% and 
60.7% to 77%, respectively. HER2/Neu-enriched carcinomas 
exhibit HER2/Neu gene overexpression, an independent poor 
prognostic factor which effect is mitigated by trastuzumab, 
anti-HER2/Neu monoclonal antibody agent.[11-13]
conclusIon
We conclude that in our setting like most others in Nigeria 
and Africa, high-grade invasive carcinoma, NST of the breast 
commonly affects young women and is predominantly of the 
triple-negative molecular phenotype. Thus, we recommend that 
as much as possible, immunophenotyping to stratify patients 
and provide rational basis for tailored treatment should be 
pursued.
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